Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02109627 · ClinicalTrials.gov registry record · Phase 1
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
A Phase 1 study, sponsored by C. Babis Andreadis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02109627 is a Phase 1 study that was terminated before completion, run by C. Babis Andreadis. The registered enrollment target is 17 participants.
The verdict
NCT02109627, a Phase 1 study, was terminated before completion, sponsored by C. Babis Andreadis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to see if ficlatuzumab when combined with cytarabine, a standard treatment for AML, is safe to give to patients and to determine the best dose to give. The study doctors want to see what effects, good and/or bad, the study drug has on subjects and their AML. The study will look at what side effects subjects may have and how subjects feel after receiving the study drug.
Interventions
- DRUG Cytarabine
- DRUG Ficlatuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2019-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02109627
The ClinicalTrials.gov registry entry for NCT02109627 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. Babis Andreadis, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT02109627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02109627 about?
NCT02109627 is a clinical study titled "Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML". The purpose of this study is to see if ficlatuzumab when combined with cytarabine, a standard treatment for AML, is safe to give to patients and to determine the best dose to give. The study doctors want to see what effects, good and/or bad, the study drug has on subjects and their AML. The study wi...
What is the current status of trial NCT02109627?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2015-05-01. Estimated completion is 2019-12-02.
What interventions are being tested in trial NCT02109627?
The interventions under investigation include: Cytarabine (DRUG), Ficlatuzumab (DRUG).
Who is sponsoring clinical trial NCT02109627?
This trial is sponsored by C. Babis Andreadis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.